Steve Duffy

Digital Content Editor

Most Recent Articles by Steve Duffy

Novel Narcolepsy Treatment Gets Orphan Drug Designation

Novel Narcolepsy Treatment Gets Orphan Drug Designation

By

The Company stated that they plan to begin a Phase 2 trial of AXS-12 before the end of 2018, with results anticipated for the first half of 2019.

Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis

Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis

By

Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia.

FDA Fast-Tracks Non-Opioid Treatment for Neuropathic Pain

FDA Fast-Tracks Non-Opioid Treatment for Neuropathic Pain

By

The treatment is currently being evaluated in a Phase 2 study (ELEVATE) in patients with major depressive disorder who have had an inadequate response to standard antidepressant therapy.

Fycompa Approved for Younger Epilepsy Patients With Partial-Onset Seizures

Fycompa Approved for Younger Epilepsy Patients With Partial-Onset Seizures

By

Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing.

FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products

FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products

By

As part of the REMS program, drug companies with approved opioid analgesics must make training available to prescribers and provide unrestricted grants to accredited continuing education providers for the development of education courses.

More Articles by Steve Duffy

Sign Up for Free e-newsletters



CME Focus